Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction

Frank L. Dini, Erberto Carluccio, Anca Simioniuc, Paolo Biagioli, Gianpaolo Reboldi, Gian Giacomo Galeotti, Claudia Raineri, Luna Gargani, Laura Scelsi, Giulia Elena Mandoli, Antonia Cannito, A. Rossi, Pierluigi Temporelli, Stefano Ghio

Research output: Contribution to journalArticle

Abstract

Aims: A compromised tricuspid annular plane systolic excursion (TAPSE) is associated with worse survival in patients with chronic heart failure with reduced ejection fraction (HFrEF). However, it is not known whether a reversible abnormal TAPSE at follow-up predicts survival. Our aim was to evaluate whether a reversible abnormal TAPSE is associated with a better survival in patients with chronic HFrEF. Methods and results: A complete echocardiography was performed in 706 patients with chronic HFrEF (LVEF ≤45%) at baseline and after 6±3months. Right ventricular (RV) systolic function was evaluated using TAPSE. The study endpoint was all-cause mortality. At baseline, TAPSE was severely reduced (≤14mm) in 89 (13%) patients, and slightly reduced (>14 but <18mm) in 157 (22%) patients. During a median follow-up of 40 months, 152 patients reached the endpoint. The event rate (per 100 patients/year) was lower in patients with persistently normal TAPSE (≥18mm, n = 393) [3.3%, 95% confidence interval (CI) 2.5-4.3], and in those with reversible TAPSE (n = 120) (4.6%, 95% CI 3.1-7.0), compared with patients with worsening TAPSE (n = 90) (11.9%, 95% CI 8.7-16.3), and those with persistently reduced TAPSE (n = 103) (12.6%, 95% CI 9.3-17.1; log-rank 69.4, P < 0.0001). A reversible abnormal TAPSE was associated with improved survival at multivariable Cox regression analysis (hazard ratio 0.48, 95% CI 0.29-0.79, P = 0.004). Conclusions: Patients with chronic HFrEF who have abnormal TAPSE at baseline but reverse their dysfunction during follow-up have better survival than patients with either worsened TAPSE or persistently abnormal TAPSE, and similar to that of patients with persistently normal TAPSE.

Original languageEnglish
JournalEuropean Journal of Heart Failure
DOIs
Publication statusPublished - 2016

Fingerprint

Heart Failure
Survival
Confidence Intervals
Right Ventricular Function
Echocardiography
Regression Analysis
Mortality

Keywords

  • Echocardiography
  • Heart failure
  • Prognosis
  • Right ventricular function

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. / Dini, Frank L.; Carluccio, Erberto; Simioniuc, Anca; Biagioli, Paolo; Reboldi, Gianpaolo; Galeotti, Gian Giacomo; Raineri, Claudia; Gargani, Luna; Scelsi, Laura; Mandoli, Giulia Elena; Cannito, Antonia; Rossi, A.; Temporelli, Pierluigi; Ghio, Stefano.

In: European Journal of Heart Failure, 2016.

Research output: Contribution to journalArticle

Dini, Frank L. ; Carluccio, Erberto ; Simioniuc, Anca ; Biagioli, Paolo ; Reboldi, Gianpaolo ; Galeotti, Gian Giacomo ; Raineri, Claudia ; Gargani, Luna ; Scelsi, Laura ; Mandoli, Giulia Elena ; Cannito, Antonia ; Rossi, A. ; Temporelli, Pierluigi ; Ghio, Stefano. / Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction. In: European Journal of Heart Failure. 2016.
@article{6bf41e4bb599498c94693d8989583bbd,
title = "Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction",
abstract = "Aims: A compromised tricuspid annular plane systolic excursion (TAPSE) is associated with worse survival in patients with chronic heart failure with reduced ejection fraction (HFrEF). However, it is not known whether a reversible abnormal TAPSE at follow-up predicts survival. Our aim was to evaluate whether a reversible abnormal TAPSE is associated with a better survival in patients with chronic HFrEF. Methods and results: A complete echocardiography was performed in 706 patients with chronic HFrEF (LVEF ≤45{\%}) at baseline and after 6±3months. Right ventricular (RV) systolic function was evaluated using TAPSE. The study endpoint was all-cause mortality. At baseline, TAPSE was severely reduced (≤14mm) in 89 (13{\%}) patients, and slightly reduced (>14 but <18mm) in 157 (22{\%}) patients. During a median follow-up of 40 months, 152 patients reached the endpoint. The event rate (per 100 patients/year) was lower in patients with persistently normal TAPSE (≥18mm, n = 393) [3.3{\%}, 95{\%} confidence interval (CI) 2.5-4.3], and in those with reversible TAPSE (n = 120) (4.6{\%}, 95{\%} CI 3.1-7.0), compared with patients with worsening TAPSE (n = 90) (11.9{\%}, 95{\%} CI 8.7-16.3), and those with persistently reduced TAPSE (n = 103) (12.6{\%}, 95{\%} CI 9.3-17.1; log-rank 69.4, P < 0.0001). A reversible abnormal TAPSE was associated with improved survival at multivariable Cox regression analysis (hazard ratio 0.48, 95{\%} CI 0.29-0.79, P = 0.004). Conclusions: Patients with chronic HFrEF who have abnormal TAPSE at baseline but reverse their dysfunction during follow-up have better survival than patients with either worsened TAPSE or persistently abnormal TAPSE, and similar to that of patients with persistently normal TAPSE.",
keywords = "Echocardiography, Heart failure, Prognosis, Right ventricular function",
author = "Dini, {Frank L.} and Erberto Carluccio and Anca Simioniuc and Paolo Biagioli and Gianpaolo Reboldi and Galeotti, {Gian Giacomo} and Claudia Raineri and Luna Gargani and Laura Scelsi and Mandoli, {Giulia Elena} and Antonia Cannito and A. Rossi and Pierluigi Temporelli and Stefano Ghio",
year = "2016",
doi = "10.1002/ejhf.639",
language = "English",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley & Sons, Ltd",

}

TY - JOUR

T1 - Right ventricular recovery during follow-up is associated with improved survival in patients with chronic heart failure with reduced ejection fraction

AU - Dini, Frank L.

AU - Carluccio, Erberto

AU - Simioniuc, Anca

AU - Biagioli, Paolo

AU - Reboldi, Gianpaolo

AU - Galeotti, Gian Giacomo

AU - Raineri, Claudia

AU - Gargani, Luna

AU - Scelsi, Laura

AU - Mandoli, Giulia Elena

AU - Cannito, Antonia

AU - Rossi, A.

AU - Temporelli, Pierluigi

AU - Ghio, Stefano

PY - 2016

Y1 - 2016

N2 - Aims: A compromised tricuspid annular plane systolic excursion (TAPSE) is associated with worse survival in patients with chronic heart failure with reduced ejection fraction (HFrEF). However, it is not known whether a reversible abnormal TAPSE at follow-up predicts survival. Our aim was to evaluate whether a reversible abnormal TAPSE is associated with a better survival in patients with chronic HFrEF. Methods and results: A complete echocardiography was performed in 706 patients with chronic HFrEF (LVEF ≤45%) at baseline and after 6±3months. Right ventricular (RV) systolic function was evaluated using TAPSE. The study endpoint was all-cause mortality. At baseline, TAPSE was severely reduced (≤14mm) in 89 (13%) patients, and slightly reduced (>14 but <18mm) in 157 (22%) patients. During a median follow-up of 40 months, 152 patients reached the endpoint. The event rate (per 100 patients/year) was lower in patients with persistently normal TAPSE (≥18mm, n = 393) [3.3%, 95% confidence interval (CI) 2.5-4.3], and in those with reversible TAPSE (n = 120) (4.6%, 95% CI 3.1-7.0), compared with patients with worsening TAPSE (n = 90) (11.9%, 95% CI 8.7-16.3), and those with persistently reduced TAPSE (n = 103) (12.6%, 95% CI 9.3-17.1; log-rank 69.4, P < 0.0001). A reversible abnormal TAPSE was associated with improved survival at multivariable Cox regression analysis (hazard ratio 0.48, 95% CI 0.29-0.79, P = 0.004). Conclusions: Patients with chronic HFrEF who have abnormal TAPSE at baseline but reverse their dysfunction during follow-up have better survival than patients with either worsened TAPSE or persistently abnormal TAPSE, and similar to that of patients with persistently normal TAPSE.

AB - Aims: A compromised tricuspid annular plane systolic excursion (TAPSE) is associated with worse survival in patients with chronic heart failure with reduced ejection fraction (HFrEF). However, it is not known whether a reversible abnormal TAPSE at follow-up predicts survival. Our aim was to evaluate whether a reversible abnormal TAPSE is associated with a better survival in patients with chronic HFrEF. Methods and results: A complete echocardiography was performed in 706 patients with chronic HFrEF (LVEF ≤45%) at baseline and after 6±3months. Right ventricular (RV) systolic function was evaluated using TAPSE. The study endpoint was all-cause mortality. At baseline, TAPSE was severely reduced (≤14mm) in 89 (13%) patients, and slightly reduced (>14 but <18mm) in 157 (22%) patients. During a median follow-up of 40 months, 152 patients reached the endpoint. The event rate (per 100 patients/year) was lower in patients with persistently normal TAPSE (≥18mm, n = 393) [3.3%, 95% confidence interval (CI) 2.5-4.3], and in those with reversible TAPSE (n = 120) (4.6%, 95% CI 3.1-7.0), compared with patients with worsening TAPSE (n = 90) (11.9%, 95% CI 8.7-16.3), and those with persistently reduced TAPSE (n = 103) (12.6%, 95% CI 9.3-17.1; log-rank 69.4, P < 0.0001). A reversible abnormal TAPSE was associated with improved survival at multivariable Cox regression analysis (hazard ratio 0.48, 95% CI 0.29-0.79, P = 0.004). Conclusions: Patients with chronic HFrEF who have abnormal TAPSE at baseline but reverse their dysfunction during follow-up have better survival than patients with either worsened TAPSE or persistently abnormal TAPSE, and similar to that of patients with persistently normal TAPSE.

KW - Echocardiography

KW - Heart failure

KW - Prognosis

KW - Right ventricular function

UR - http://www.scopus.com/inward/record.url?scp=84988418437&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988418437&partnerID=8YFLogxK

U2 - 10.1002/ejhf.639

DO - 10.1002/ejhf.639

M3 - Article

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

SN - 1388-9842

ER -